SlideShare a Scribd company logo
Cost-benefit Analysis
1
Abdur Razzaque Sarker
MHE (Health Economics), MSS (Economics)
Health Economics and Financing Research, icddrb
and
PhD Fellow in Strathclyde University, UK
Email: razzaque.sarker@gmail.com
What is Cost-Benefit Analysis
Cost Benefit Analysis (CBA) is an economic
evaluation
technique that both costs and consequences
(benefits)
are measured in monetary unit.
Net benefit = Benefits - Costs
2
 An intervention should be undertaken
if the benefits exceed the costs.
Choose the intervention with the highest net
benefit if only one intervention can be
funded
3
Why using CBA
 Resources are limited
 The intervention program should be
economically viable
 CBA adopts a broad societal
perspective as it includes all costs and
all benefits
4
Economic evaluation methods at a glance
5
Measuring cost of intervention
The cost of intervention will be
calculated
in the same way as other economic
evaluation methods (Please see ‘cost
analysis’).
6
Measuring benefits
The ways to measure monetary value of
benefits from intervention
1. Cost of illness averted
2. Contingent valuation method
(willingness to pay)
7
1. Cost-of-illness averted
The cost of illness (COI) is defined as the
value
of the resources that are expended or
foregone
as a result of a health problem (like,
diseases).
8
Perspectives of COI
Patient’s or household’s perspective
Provider’s perspective
Societal perspective
9
Costs can be classified into
three types
 Direct Costs: Direct costs related to treating the
patients (example, doctor’s visit, drugs, transport)
 Indirect Cost: Loss of productivity of patients
and care-givers
 Intangible cost: Pain, anxiety, discomfort
10
Information needs to be collected
Direct cost
 How much patients spend for medicine.
 How much money was spent for transportation
for each visit.
 Did you spend any night away from home
regarding treatment and spend money to buy
food and lodging?
 Did you spend any money for any diagnostic
tests?
 Did you pay consultation fee to the provider?
11
Indirect cost
Examples:
 At the time you got sick with cholera, were you employed?
 How much time you waited before receiving this service?
 What was your daily wage?
 How many days had you been absent from work due to illness?
 Did anybody take care of you during your illness?
 How many days she/he had been absent from work for giving you
care?
 What was her/his daily wage?
 more……
12
Information needs to be collected
Intangible cost
Difficult to measure and often a limitation of the study
13
Information needs to be collected
Provider’s actual cost of illness
Provider actual cost of illness will be calculated as
the provider’s cost for treatment excluding any fees
received from the patients for hospitalization, drug,
diagnostic tests etc.
If government implements vaccination against
cholera. The cholera hospitals (wards) can be
benefited by reducing their cost for treating cholera
patients.
14
It includes cost of providers, cost of patients or
households and costs of insurance company (if
applicable)
15
Cost of illness of society
The cost of illness that can be averted,
i.e.
benefits of the intervention will then be
adjusted for time differentials using
discount rate.
16
17
Costs Parameters Average cost Standard deviation %of total cost
Direct Medical Diagnostic 9.6 (0.1) 75.7 (1) 9
Medicine 148.7 (2) 246 (3.)
Registration fee 26.1 (0.3) 130.6 (1.7)
Paramedics home visit fee 2.8 (−) 21.5 (0.3)
Bed/ Cabin charge 16.9 (0.2) 130.7 (1.7)
Direct Non-
Medical
Transportation cost 140 (1.9) 122 (1.6) 15.6
food items 63(0.8) 85 (1.1)
Informal payment 0.7 (−) 9 (0.1)
Caregivers payment 0.1 (−) 1 (−)
Materials (mug/glass/coil etc) 10.6(0.1) 17 (0.2)
Lodging 28 (0.4) 101 (1.3)
Caregivers expenditure 113.2 (1.5) 172 (2.3)
Total direct cost 559.5 (7.4) 641.7 (8.5) 24.6
In-direct Patients income loss 811 (11) 4,301 (57)
Caregivers income loss 908 (12.2) 3,701 (49)
Total indirect cost 1,719 (23) 5,656 (75.4) 75.4
Total cost of illness of household 2,278.5 (30.4) 5,668 (75.6) 100
Average household cost for cholera treatment
18
Suppose in Mirpur area, every year 1200 patients are
affected by Cholera diseases and it is estimated by
our hospital record. A Cost of illness study
conducted and estimate the average cost for treating
cholera is $40 from societal perspective. We want to
minimized the burden of cholera diseases and he
initiated the following three intervention
A Only Vaccination
B Vaccination & hand washing technique
C Vaccine, hand washing & Water treatment
procedure
19
Intervention Total cost (C)
Outcome
(No of case averted)
A (Vaccine) 10000 200
B ( Vaccine & hand washing) 15000 650
C (Vaccine, hand washing and
water treatment) 18000 900
We want to know which intervention is
sustainable based on cost benefit analysis?
20
Decision tools:
 Net Social Benefit (NSB) = B-C
 If B > C we take the intervention, i.e. B-C
>0, we accepted that program
 If B< C i.e. B-C <0, we must rejected that
intervention
 If B = C , i.e. B-C =0, we are indifferent i.e.
it may be accepted or rejected
21
Intervention Total cost (C)
Outcome
(No of case averted)
A (Vaccine) 10000 200
B ( Vaccine & hand washing) 15000 650
C (Vaccine, hand washing and
water treatment) 18000 900
Intervention
Total cost
(C)
Outcome
(No of case averted)
Total Benefit
(B)
A (Vaccine) 10000 200 8,000
B ( Vaccine & hand washing) 15000 650 26,000
C (Vaccine, hand washing &
Water treatment) 18000 900 36,000
Since average COI is $40 for societal perspective
22
Intervention
Total cost
(C)
Outcome
(No of case
averted)
Total
Benefit (B)
Net Social
Benefit
(NSB = B-C )
A (Vaccine) 10000 500 8,000 -2,000
B ( Vaccine &
handwashing) 15000 650 26,000 11000
C (Vaccine, hand washing
& Water treatment) 18000 900 36,000 18000
 If we consider intervention A , here, B – C < 0, Rejected A
 In intervention B, here, B –C > 0, ie. NSB >0. Accepted B
In intervention C, here, B – C > 0, i,e. NSB >0. Accepted c
If we compare all that program, only one intervention can be
funded than alternative C is better, causes it gives higher net
social benefit.
23
Assigning Money Values in health
outcomes
 Human Capital Approaches
Cost of illness
 Contingent valuation method (CVM)
Willingness-to- Pay (WTP) Method
Willingness –to- Accept (WTP) Method
 CVM is a direct method which involves asking a
sample of the relevant population question about
their willingness to pay (WTP) for a certain product
(health intervention program)
 Willingness to pay (WTP) is the maximum amount
a
person would be willing to pay, sacrifice or
exchange in
order to receive a good or to avoid risk
 If individuals answer truthfully, their answers will
24
2. Contingent valuation method
(CVM)
CV question can be divided into open-
ended and discrete choice.
Open-ended
Using bidding game technique respondents
are asked to state their maximum WTP for
the benefit of a specific intervention.
25
26
To introduce the cholera vaccine we asked
to all household head to know what they
willing to pay (max. WTP) to avoidable this
loss (COI).
 Did you agree to pay for two doses cholera
vaccine
Yes…..(1)
No….(2)
 How much you want to pay for two doses
oral Cholera vaccine ?
BDT……………………
27
 In bidding game (like an auction),
respondents are offered with a bid for
acceptance or rejection. Depending on
respondent’s answer, the bid is then lowered or
increased until respondent’s maximum WTP is
reached.
 We bid a price to household head and know
about his WTP which may be increasing or
decreasing. And finally we select final WTP.
Discrete
Respondents are offered a bid and asked for
either accepting or rejecting. Using different
bids in different sub-samples, it is possible to
calculate the percentage of respondents who
are willing to pay as a function of price (bid).
28
29
 Did you agree to pay for two doses
cholera vaccine
Yes…..(1)
No….(2)
 If Yes, then which price …
3*2 = 6 USD per family member….....(1)
4*2 = 8 USD per family member…….(2)
4.5*2= 9 USD per family member…….(3)
5*2 =10 USD per family member…….(4)
5.5*2 =11 USD per family member…….(5)
Survey for contingent valuation
Creating a survey instrument for capturing
individuals' WTP
(a) designing the hypothetical scenario;
(b) creating a scenario about the means of
payment
Use the survey instrument with a sample of
the population of interest
30
31
Where,
i= indexes respondents
Y= Income
E= Education
A = Age
D=disease or health risk exposure experience
WTPi =
f
(
Yi, Ei, Ai, Di, ... )
Total WTP is achieved by deriving the
population average WTP from the data and
multiplying it by the population size, N.
32
Note to interviewer:
Describe the cholera vaccine, dose and effectiveness both for adult and child to the respondents following
the structured description of the product.
Would you be willing to pay X Taka for full vaccination
for you?
Yes
No
If yes, please explain your reasons for agreeing to pay? 1. The amount is affordable
2. I don’t want to suffer from cholera
Other, specify ___________
If no, pls explain your reasons for not wanting to pay? 1. Too expensive
2. Unable to pay
Other, specify ____________
Would you be willing to pay XX Taka for full vaccination
for other members of your family?
Yes
No
If yes, please explain your reasons for agreeing to pay? 1. The amount is affordable
2. I don’t want to suffer from cholera
Other, specify ___________
If no, pls explain your reasons for not wanting to pay? 1. Too expensive
2. Unable to pay
Other, specify ____________
What would be the maximum amount you would be
willing to pay for yourself?
______________________ Tk
What would be the maximum amount you would be
willing to pay for other family members?
______________________ Tk
Total benefit of the proposed intervention can be calculated by
multiplying average WTP with total number of population in
interest group.
Benefits of the intervention (WTP) will then be adjusted for time
differentials using discount rate.
Example,
Total WTP = 10,000 Taka (after discounting)
Total cost of intervention = 8,000 Taka (after discounting)
Net benefit = 10,000 – 8,000 Taka = 2,000 Taka
Conclusion: If net benefit is higher than zero, then intervention
program is acceptable
33
THANKS
34
Email: razzaque.sarker@gmail.com

More Related Content

What's hot

Cost Benefit Analysis in Health Care
Cost Benefit Analysis in Health CareCost Benefit Analysis in Health Care
Cost Benefit Analysis in Health Care
Prabesh Ghimire
 
Cost Effectiveness Analysis in Health Care
Cost Effectiveness Analysis in Health CareCost Effectiveness Analysis in Health Care
Cost Effectiveness Analysis in Health Care
Prabesh Ghimire
 
Health economics
Health economicsHealth economics
Health economics
Devangi Sharma
 
Cost Utility Analysis
Cost Utility AnalysisCost Utility Analysis
Cost Utility Analysis
LanceCatedral
 
Cost utility analysis
Cost utility analysisCost utility analysis
Cost utility analysis
ARUNAYESUDAS
 
Cost concept and economic evaluation
Cost concept and economic evaluationCost concept and economic evaluation
Cost concept and economic evaluation
Birat Medical College, Kathmandu University, Nepal
 
Health economics
Health economicsHealth economics
Health economics
Amit Pagada
 
Healthcare Economic evaluation
Healthcare Economic evaluationHealthcare Economic evaluation
Healthcare Economic evaluation
BPKIHS
 
Health economics what is it
Health economics what is itHealth economics what is it
Health economics what is it
Dr (Gp Capt) S Mankar
 
Health economics and evaluation of healthcare
Health economics and evaluation of healthcareHealth economics and evaluation of healthcare
Health economics and evaluation of healthcare
HithaUdayabhanu1
 
Measures of association - Biostatistics
Measures of association - BiostatisticsMeasures of association - Biostatistics
Measures of association - Biostatistics
HelpWithAssignment.com
 
Health economics
Health economicsHealth economics
Health economics
Abdur Razzaque Sarker, PhD
 
Cost effectiveness analysis
Cost effectiveness analysisCost effectiveness analysis
Cost effectiveness analysis
zeekooo
 
Pharmacoeconomics
Pharmacoeconomics Pharmacoeconomics
Pharmacoeconomics
academic
 
Measurement of outcomes in epidemiology
Measurement of outcomes in epidemiologyMeasurement of outcomes in epidemiology
Measurement of outcomes in epidemiology
Dr. Ankit Gaur
 
Principles of health economics
Principles of health economicsPrinciples of health economics
Principles of health economics
Ankita Kunwar
 
Concept of Economic Evaluation in Health Care
Concept of Economic Evaluation in Health CareConcept of Economic Evaluation in Health Care
Concept of Economic Evaluation in Health Care
Prabesh Ghimire
 
Prescription Event Monitoring & Record Linkage Systems
Prescription Event Monitoring & Record Linkage SystemsPrescription Event Monitoring & Record Linkage Systems
Prescription Event Monitoring & Record Linkage Systems
Satish Veerla
 
Catastrophic health expenditure and poverty and Malawi by Martina Rhino Mchenga
Catastrophic health expenditure and poverty and Malawi by Martina Rhino MchengaCatastrophic health expenditure and poverty and Malawi by Martina Rhino Mchenga
Catastrophic health expenditure and poverty and Malawi by Martina Rhino Mchenga
IFPRIMaSSP
 
Introduction to budget impact analysis
Introduction to budget impact analysisIntroduction to budget impact analysis
Introduction to budget impact analysis
NazmiLianaAzmi
 

What's hot (20)

Cost Benefit Analysis in Health Care
Cost Benefit Analysis in Health CareCost Benefit Analysis in Health Care
Cost Benefit Analysis in Health Care
 
Cost Effectiveness Analysis in Health Care
Cost Effectiveness Analysis in Health CareCost Effectiveness Analysis in Health Care
Cost Effectiveness Analysis in Health Care
 
Health economics
Health economicsHealth economics
Health economics
 
Cost Utility Analysis
Cost Utility AnalysisCost Utility Analysis
Cost Utility Analysis
 
Cost utility analysis
Cost utility analysisCost utility analysis
Cost utility analysis
 
Cost concept and economic evaluation
Cost concept and economic evaluationCost concept and economic evaluation
Cost concept and economic evaluation
 
Health economics
Health economicsHealth economics
Health economics
 
Healthcare Economic evaluation
Healthcare Economic evaluationHealthcare Economic evaluation
Healthcare Economic evaluation
 
Health economics what is it
Health economics what is itHealth economics what is it
Health economics what is it
 
Health economics and evaluation of healthcare
Health economics and evaluation of healthcareHealth economics and evaluation of healthcare
Health economics and evaluation of healthcare
 
Measures of association - Biostatistics
Measures of association - BiostatisticsMeasures of association - Biostatistics
Measures of association - Biostatistics
 
Health economics
Health economicsHealth economics
Health economics
 
Cost effectiveness analysis
Cost effectiveness analysisCost effectiveness analysis
Cost effectiveness analysis
 
Pharmacoeconomics
Pharmacoeconomics Pharmacoeconomics
Pharmacoeconomics
 
Measurement of outcomes in epidemiology
Measurement of outcomes in epidemiologyMeasurement of outcomes in epidemiology
Measurement of outcomes in epidemiology
 
Principles of health economics
Principles of health economicsPrinciples of health economics
Principles of health economics
 
Concept of Economic Evaluation in Health Care
Concept of Economic Evaluation in Health CareConcept of Economic Evaluation in Health Care
Concept of Economic Evaluation in Health Care
 
Prescription Event Monitoring & Record Linkage Systems
Prescription Event Monitoring & Record Linkage SystemsPrescription Event Monitoring & Record Linkage Systems
Prescription Event Monitoring & Record Linkage Systems
 
Catastrophic health expenditure and poverty and Malawi by Martina Rhino Mchenga
Catastrophic health expenditure and poverty and Malawi by Martina Rhino MchengaCatastrophic health expenditure and poverty and Malawi by Martina Rhino Mchenga
Catastrophic health expenditure and poverty and Malawi by Martina Rhino Mchenga
 
Introduction to budget impact analysis
Introduction to budget impact analysisIntroduction to budget impact analysis
Introduction to budget impact analysis
 

Viewers also liked

"Cost of illness studies in rare diseases: cystic fibrosis as an example" by ...
"Cost of illness studies in rare diseases: cystic fibrosis as an example" by ..."Cost of illness studies in rare diseases: cystic fibrosis as an example" by ...
"Cost of illness studies in rare diseases: cystic fibrosis as an example" by ...
Vall d'Hebron Institute of Research (VHIR)
 
Cost Benifit Analysis
Cost Benifit AnalysisCost Benifit Analysis
Cost Benifit Analysis
Tareq Zarouni
 
Benifit cost analysis
Benifit cost analysisBenifit cost analysis
Benifit cost analysis
jnujaipur
 
Cost-benefit analysis
Cost-benefit analysisCost-benefit analysis
Cost-benefit analysis
Soniya Balan
 
Cost-Benefit Analysis
Cost-Benefit AnalysisCost-Benefit Analysis
Cost-Benefit Analysis
Sakshi Sharma
 
Health economics
Health economicsHealth economics
Health economics
ancychacko89
 
Session 13 francesc_palau
Session 13 francesc_palauSession 13 francesc_palau
Session 13 francesc_palau
EURORDIS - Rare Diseases Europe
 
Rare diseases
Rare diseasesRare diseases
Rare diseases
Joann Haase
 
Nbs manual 28-6-2015
Nbs manual 28-6-2015 Nbs manual 28-6-2015
Nbs manual 28-6-2015
Newborn Screening KW
 
Fundamental Diseases: Why We Should Care About The Rare
Fundamental Diseases: Why We Should Care About The RareFundamental Diseases: Why We Should Care About The Rare
Fundamental Diseases: Why We Should Care About The Rare
Findacure
 
Similarities and differences between Rare Cancers and Rare Diseases
Similarities and differences between Rare Cancers and Rare DiseasesSimilarities and differences between Rare Cancers and Rare Diseases
Similarities and differences between Rare Cancers and Rare Diseases
jangeissler
 
Cluj
ClujCluj
Newborn screening kuwait
Newborn screening kuwaitNewborn screening kuwait
Newborn screening kuwait
Newborn Screening KW
 
Genomics: Shifting the Paradigm for Rare Diseases
Genomics: Shifting the Paradigm for Rare DiseasesGenomics: Shifting the Paradigm for Rare Diseases
Genomics: Shifting the Paradigm for Rare Diseases
Hannes Smárason
 
Multidisciplinary teams for diagnosis and treatment of children (and adults) ...
Multidisciplinary teams for diagnosis and treatment of children (and adults) ...Multidisciplinary teams for diagnosis and treatment of children (and adults) ...
Multidisciplinary teams for diagnosis and treatment of children (and adults) ...
Canadian Organization for Rare Disorders
 
Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...
Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...
Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...
Canadian Organization for Rare Disorders
 
Vibrio cholerae
Vibrio choleraeVibrio cholerae
Vibrio cholerae
camiij1
 
Gene therapy
Gene therapyGene therapy
Gene therapy
Paul singh
 
Investment Analysis Project Presentation
Investment Analysis  Project PresentationInvestment Analysis  Project Presentation
Investment Analysis Project Presentation
nroopraj24
 
Risk analysis and management
Risk analysis and managementRisk analysis and management
Risk analysis and management
gnitu
 

Viewers also liked (20)

"Cost of illness studies in rare diseases: cystic fibrosis as an example" by ...
"Cost of illness studies in rare diseases: cystic fibrosis as an example" by ..."Cost of illness studies in rare diseases: cystic fibrosis as an example" by ...
"Cost of illness studies in rare diseases: cystic fibrosis as an example" by ...
 
Cost Benifit Analysis
Cost Benifit AnalysisCost Benifit Analysis
Cost Benifit Analysis
 
Benifit cost analysis
Benifit cost analysisBenifit cost analysis
Benifit cost analysis
 
Cost-benefit analysis
Cost-benefit analysisCost-benefit analysis
Cost-benefit analysis
 
Cost-Benefit Analysis
Cost-Benefit AnalysisCost-Benefit Analysis
Cost-Benefit Analysis
 
Health economics
Health economicsHealth economics
Health economics
 
Session 13 francesc_palau
Session 13 francesc_palauSession 13 francesc_palau
Session 13 francesc_palau
 
Rare diseases
Rare diseasesRare diseases
Rare diseases
 
Nbs manual 28-6-2015
Nbs manual 28-6-2015 Nbs manual 28-6-2015
Nbs manual 28-6-2015
 
Fundamental Diseases: Why We Should Care About The Rare
Fundamental Diseases: Why We Should Care About The RareFundamental Diseases: Why We Should Care About The Rare
Fundamental Diseases: Why We Should Care About The Rare
 
Similarities and differences between Rare Cancers and Rare Diseases
Similarities and differences between Rare Cancers and Rare DiseasesSimilarities and differences between Rare Cancers and Rare Diseases
Similarities and differences between Rare Cancers and Rare Diseases
 
Cluj
ClujCluj
Cluj
 
Newborn screening kuwait
Newborn screening kuwaitNewborn screening kuwait
Newborn screening kuwait
 
Genomics: Shifting the Paradigm for Rare Diseases
Genomics: Shifting the Paradigm for Rare DiseasesGenomics: Shifting the Paradigm for Rare Diseases
Genomics: Shifting the Paradigm for Rare Diseases
 
Multidisciplinary teams for diagnosis and treatment of children (and adults) ...
Multidisciplinary teams for diagnosis and treatment of children (and adults) ...Multidisciplinary teams for diagnosis and treatment of children (and adults) ...
Multidisciplinary teams for diagnosis and treatment of children (and adults) ...
 
Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...
Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...
Managed Access Programs: Timely, Appropriate, Sustainable Access for Rare Dis...
 
Vibrio cholerae
Vibrio choleraeVibrio cholerae
Vibrio cholerae
 
Gene therapy
Gene therapyGene therapy
Gene therapy
 
Investment Analysis Project Presentation
Investment Analysis  Project PresentationInvestment Analysis  Project Presentation
Investment Analysis Project Presentation
 
Risk analysis and management
Risk analysis and managementRisk analysis and management
Risk analysis and management
 

Similar to Cost benifit analysis

Seminar on health economic copy
Seminar on health economic   copySeminar on health economic   copy
Seminar on health economic copy
Preeti Rai
 
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
GlobalResearchUCSF
 
1 gf h econ slides basics
1 gf h econ slides basics1 gf h econ slides basics
1 gf h econ slides basics
Greg Fell
 
lect_3_4_schwartzman_economic_analyses_tb_course_2015.ppt
lect_3_4_schwartzman_economic_analyses_tb_course_2015.pptlect_3_4_schwartzman_economic_analyses_tb_course_2015.ppt
lect_3_4_schwartzman_economic_analyses_tb_course_2015.ppt
Dhanang Nugraha
 
Using financial incentives to increase testing uptake versie 2
Using financial incentives to increase testing uptake versie 2Using financial incentives to increase testing uptake versie 2
Using financial incentives to increase testing uptake versie 2
Jennie van de Weerd
 
Health Technology Assessment- Overview
Health Technology Assessment- OverviewHealth Technology Assessment- Overview
Health Technology Assessment- Overview
shashi sinha
 
HCA 205 Week 2 Quiz Assiignment 3.docx
HCA 205 Week 2 Quiz Assiignment 3.docxHCA 205 Week 2 Quiz Assiignment 3.docx
HCA 205 Week 2 Quiz Assiignment 3.docx
sdfghj21
 
Health economics
Health economicsHealth economics
Health economics
dipesh125
 
Nguyễn Duy Anh - Báo cáo oral.pdf
Nguyễn Duy Anh - Báo cáo oral.pdfNguyễn Duy Anh - Báo cáo oral.pdf
Nguyễn Duy Anh - Báo cáo oral.pdf
Son Nguyen
 
Assignment Exercise 4–1 Contractual Allowances Physician office.docx
Assignment Exercise 4–1 Contractual Allowances Physician office.docxAssignment Exercise 4–1 Contractual Allowances Physician office.docx
Assignment Exercise 4–1 Contractual Allowances Physician office.docx
rock73
 
An Introduction to Health Economics
An Introduction to Health EconomicsAn Introduction to Health Economics
An Introduction to Health Economics
Pharmacy @ Institut Kanser Negara
 
2 tool to estimate patient costs literature review_final
2 tool to estimate patient costs literature review_final2 tool to estimate patient costs literature review_final
2 tool to estimate patient costs literature review_final
Aira Bhabe
 
UNIT 3 .pptx
UNIT 3 .pptxUNIT 3 .pptx
UNIT 3 .pptx
SonamOngmu3
 
Wound care in the Physical Therapy Private Practice Outpatient Sector: A busi...
Wound care in the Physical Therapy Private Practice Outpatient Sector: A busi...Wound care in the Physical Therapy Private Practice Outpatient Sector: A busi...
Wound care in the Physical Therapy Private Practice Outpatient Sector: A busi...
Michelle Stauffer
 
Rural Urgent Care Centers Business PlanI. Executive Summar.docx
Rural Urgent Care Centers Business PlanI. Executive Summar.docxRural Urgent Care Centers Business PlanI. Executive Summar.docx
Rural Urgent Care Centers Business PlanI. Executive Summar.docx
anhlodge
 
Pharmacoeconomics (Basics for MD Pharmacology)
Pharmacoeconomics (Basics for MD Pharmacology)Pharmacoeconomics (Basics for MD Pharmacology)
Pharmacoeconomics (Basics for MD Pharmacology)
Dr. Advaitha MV
 
Healthy Savings. Medical Technology and the Economic Burden of Disease
Healthy Savings. Medical Technology and the Economic Burden of DiseaseHealthy Savings. Medical Technology and the Economic Burden of Disease
Healthy Savings. Medical Technology and the Economic Burden of Disease
Revital (Tali) Hirsch
 
ISPOR Special Task Force on US Value Frameworks: A Non-US Perspective
ISPOR Special Task Force on US Value Frameworks: A Non-US PerspectiveISPOR Special Task Force on US Value Frameworks: A Non-US Perspective
ISPOR Special Task Force on US Value Frameworks: A Non-US Perspective
Office of Health Economics
 
Framework for assessing the economic costs and burdens of zoonotic disease
Framework for assessing the economic costs and burdens of zoonotic diseaseFramework for assessing the economic costs and burdens of zoonotic disease
Framework for assessing the economic costs and burdens of zoonotic disease
ILRI
 
BHA 3002, Health Care Management 1 Course Learning Ou.docx
BHA 3002, Health Care Management 1 Course Learning Ou.docxBHA 3002, Health Care Management 1 Course Learning Ou.docx
BHA 3002, Health Care Management 1 Course Learning Ou.docx
tarifarmarie
 

Similar to Cost benifit analysis (20)

Seminar on health economic copy
Seminar on health economic   copySeminar on health economic   copy
Seminar on health economic copy
 
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
Comparative Effectiveness: UCSF East Africa Global Health -Kisumu 2014
 
1 gf h econ slides basics
1 gf h econ slides basics1 gf h econ slides basics
1 gf h econ slides basics
 
lect_3_4_schwartzman_economic_analyses_tb_course_2015.ppt
lect_3_4_schwartzman_economic_analyses_tb_course_2015.pptlect_3_4_schwartzman_economic_analyses_tb_course_2015.ppt
lect_3_4_schwartzman_economic_analyses_tb_course_2015.ppt
 
Using financial incentives to increase testing uptake versie 2
Using financial incentives to increase testing uptake versie 2Using financial incentives to increase testing uptake versie 2
Using financial incentives to increase testing uptake versie 2
 
Health Technology Assessment- Overview
Health Technology Assessment- OverviewHealth Technology Assessment- Overview
Health Technology Assessment- Overview
 
HCA 205 Week 2 Quiz Assiignment 3.docx
HCA 205 Week 2 Quiz Assiignment 3.docxHCA 205 Week 2 Quiz Assiignment 3.docx
HCA 205 Week 2 Quiz Assiignment 3.docx
 
Health economics
Health economicsHealth economics
Health economics
 
Nguyễn Duy Anh - Báo cáo oral.pdf
Nguyễn Duy Anh - Báo cáo oral.pdfNguyễn Duy Anh - Báo cáo oral.pdf
Nguyễn Duy Anh - Báo cáo oral.pdf
 
Assignment Exercise 4–1 Contractual Allowances Physician office.docx
Assignment Exercise 4–1 Contractual Allowances Physician office.docxAssignment Exercise 4–1 Contractual Allowances Physician office.docx
Assignment Exercise 4–1 Contractual Allowances Physician office.docx
 
An Introduction to Health Economics
An Introduction to Health EconomicsAn Introduction to Health Economics
An Introduction to Health Economics
 
2 tool to estimate patient costs literature review_final
2 tool to estimate patient costs literature review_final2 tool to estimate patient costs literature review_final
2 tool to estimate patient costs literature review_final
 
UNIT 3 .pptx
UNIT 3 .pptxUNIT 3 .pptx
UNIT 3 .pptx
 
Wound care in the Physical Therapy Private Practice Outpatient Sector: A busi...
Wound care in the Physical Therapy Private Practice Outpatient Sector: A busi...Wound care in the Physical Therapy Private Practice Outpatient Sector: A busi...
Wound care in the Physical Therapy Private Practice Outpatient Sector: A busi...
 
Rural Urgent Care Centers Business PlanI. Executive Summar.docx
Rural Urgent Care Centers Business PlanI. Executive Summar.docxRural Urgent Care Centers Business PlanI. Executive Summar.docx
Rural Urgent Care Centers Business PlanI. Executive Summar.docx
 
Pharmacoeconomics (Basics for MD Pharmacology)
Pharmacoeconomics (Basics for MD Pharmacology)Pharmacoeconomics (Basics for MD Pharmacology)
Pharmacoeconomics (Basics for MD Pharmacology)
 
Healthy Savings. Medical Technology and the Economic Burden of Disease
Healthy Savings. Medical Technology and the Economic Burden of DiseaseHealthy Savings. Medical Technology and the Economic Burden of Disease
Healthy Savings. Medical Technology and the Economic Burden of Disease
 
ISPOR Special Task Force on US Value Frameworks: A Non-US Perspective
ISPOR Special Task Force on US Value Frameworks: A Non-US PerspectiveISPOR Special Task Force on US Value Frameworks: A Non-US Perspective
ISPOR Special Task Force on US Value Frameworks: A Non-US Perspective
 
Framework for assessing the economic costs and burdens of zoonotic disease
Framework for assessing the economic costs and burdens of zoonotic diseaseFramework for assessing the economic costs and burdens of zoonotic disease
Framework for assessing the economic costs and burdens of zoonotic disease
 
BHA 3002, Health Care Management 1 Course Learning Ou.docx
BHA 3002, Health Care Management 1 Course Learning Ou.docxBHA 3002, Health Care Management 1 Course Learning Ou.docx
BHA 3002, Health Care Management 1 Course Learning Ou.docx
 

More from Abdur Razzaque Sarker, PhD

Scientific Report Writing.pdf
Scientific Report Writing.pdfScientific Report Writing.pdf
Scientific Report Writing.pdf
Abdur Razzaque Sarker, PhD
 
Cost Analysis_ Case Study
Cost Analysis_ Case StudyCost Analysis_ Case Study
Cost Analysis_ Case Study
Abdur Razzaque Sarker, PhD
 
Cost analysis
Cost analysisCost analysis
Disability Adjusted Life Years
Disability Adjusted Life YearsDisability Adjusted Life Years
Disability Adjusted Life Years
Abdur Razzaque Sarker, PhD
 
Tools for health economics
Tools for health economicsTools for health economics
Tools for health economics
Abdur Razzaque Sarker, PhD
 
Measuring health
Measuring healthMeasuring health
Measuring health
Abdur Razzaque Sarker, PhD
 
Universal health coverage
Universal health coverageUniversal health coverage
Universal health coverage
Abdur Razzaque Sarker, PhD
 
Resource allocation
Resource allocationResource allocation
Resource allocation
Abdur Razzaque Sarker, PhD
 
Health system
Health systemHealth system
Health insurence
Health insurenceHealth insurence
Health insurence
Abdur Razzaque Sarker, PhD
 
Equity in health system
Equity in health systemEquity in health system
Equity in health system
Abdur Razzaque Sarker, PhD
 
Basics health economics
Basics health economicsBasics health economics
Basics health economics
Abdur Razzaque Sarker, PhD
 
Micro economics tools for health economics
Micro economics tools for health economicsMicro economics tools for health economics
Micro economics tools for health economics
Abdur Razzaque Sarker, PhD
 
Health economics an overview
Health economics an overviewHealth economics an overview
Health economics an overview
Abdur Razzaque Sarker, PhD
 
Burden of Disease using DALYs
Burden of Disease using DALYsBurden of Disease using DALYs
Burden of Disease using DALYs
Abdur Razzaque Sarker, PhD
 
Disabilty Adjusted Life Years(DALYs)
Disabilty Adjusted Life Years(DALYs)Disabilty Adjusted Life Years(DALYs)
Disabilty Adjusted Life Years(DALYs)
Abdur Razzaque Sarker, PhD
 

More from Abdur Razzaque Sarker, PhD (16)

Scientific Report Writing.pdf
Scientific Report Writing.pdfScientific Report Writing.pdf
Scientific Report Writing.pdf
 
Cost Analysis_ Case Study
Cost Analysis_ Case StudyCost Analysis_ Case Study
Cost Analysis_ Case Study
 
Cost analysis
Cost analysisCost analysis
Cost analysis
 
Disability Adjusted Life Years
Disability Adjusted Life YearsDisability Adjusted Life Years
Disability Adjusted Life Years
 
Tools for health economics
Tools for health economicsTools for health economics
Tools for health economics
 
Measuring health
Measuring healthMeasuring health
Measuring health
 
Universal health coverage
Universal health coverageUniversal health coverage
Universal health coverage
 
Resource allocation
Resource allocationResource allocation
Resource allocation
 
Health system
Health systemHealth system
Health system
 
Health insurence
Health insurenceHealth insurence
Health insurence
 
Equity in health system
Equity in health systemEquity in health system
Equity in health system
 
Basics health economics
Basics health economicsBasics health economics
Basics health economics
 
Micro economics tools for health economics
Micro economics tools for health economicsMicro economics tools for health economics
Micro economics tools for health economics
 
Health economics an overview
Health economics an overviewHealth economics an overview
Health economics an overview
 
Burden of Disease using DALYs
Burden of Disease using DALYsBurden of Disease using DALYs
Burden of Disease using DALYs
 
Disabilty Adjusted Life Years(DALYs)
Disabilty Adjusted Life Years(DALYs)Disabilty Adjusted Life Years(DALYs)
Disabilty Adjusted Life Years(DALYs)
 

Recently uploaded

Pneumothorax and role of Physiotherapy in it.
Pneumothorax and role of Physiotherapy in it.Pneumothorax and role of Physiotherapy in it.
Pneumothorax and role of Physiotherapy in it.
Vishal kr Thakur
 
Top Rated Massage Center In Ajman Chandrima Spa
Top Rated Massage Center In Ajman Chandrima SpaTop Rated Massage Center In Ajman Chandrima Spa
Top Rated Massage Center In Ajman Chandrima Spa
Chandrima Spa Ajman
 
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...
rightmanforbloodline
 
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSONNEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
SHAMIN EABENSON
 
Innovative Minds France's Most Impactful Healthcare Leaders.pdf
Innovative Minds France's Most Impactful Healthcare Leaders.pdfInnovative Minds France's Most Impactful Healthcare Leaders.pdf
Innovative Minds France's Most Impactful Healthcare Leaders.pdf
eurohealthleaders
 
DRAFT Ventilator Rapid Reference version 2.4.pdf
DRAFT Ventilator Rapid Reference  version  2.4.pdfDRAFT Ventilator Rapid Reference  version  2.4.pdf
DRAFT Ventilator Rapid Reference version 2.4.pdf
Robert Cole
 
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Levi Shapiro
 
Under Pressure : Kenneth Kruk's Strategy
Under Pressure : Kenneth Kruk's StrategyUnder Pressure : Kenneth Kruk's Strategy
Under Pressure : Kenneth Kruk's Strategy
Kenneth Kruk
 
NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022
nktiacc3
 
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdfChampions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
eurohealthleaders
 
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareStem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Dr. David Greene Arizona
 
KEY Points of Leicester travel clinic In London doc.docx
KEY Points of Leicester travel clinic In London doc.docxKEY Points of Leicester travel clinic In London doc.docx
KEY Points of Leicester travel clinic In London doc.docx
NX Healthcare
 
Gemma Wean- Nutritional solution for Artemia
Gemma Wean- Nutritional solution for ArtemiaGemma Wean- Nutritional solution for Artemia
Gemma Wean- Nutritional solution for Artemia
smuskaan0008
 
Anxiety, Trauma and Stressor Related Disorder.pptx
Anxiety, Trauma and Stressor Related Disorder.pptxAnxiety, Trauma and Stressor Related Disorder.pptx
Anxiety, Trauma and Stressor Related Disorder.pptx
Sagunlohala1
 
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareLGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
VITASAuthor
 
Bringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured ApproachBringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured Approach
Brian Frerichs
 
Unlocking the Secrets to Safe Patient Handling.pdf
Unlocking the Secrets to Safe Patient Handling.pdfUnlocking the Secrets to Safe Patient Handling.pdf
Unlocking the Secrets to Safe Patient Handling.pdf
Lift Ability
 
Letter to MREC - application to conduct study
Letter to MREC - application to conduct studyLetter to MREC - application to conduct study
Letter to MREC - application to conduct study
Azreen Aj
 
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
rightmanforbloodline
 
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COMHUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
priyabhojwani1200
 

Recently uploaded (20)

Pneumothorax and role of Physiotherapy in it.
Pneumothorax and role of Physiotherapy in it.Pneumothorax and role of Physiotherapy in it.
Pneumothorax and role of Physiotherapy in it.
 
Top Rated Massage Center In Ajman Chandrima Spa
Top Rated Massage Center In Ajman Chandrima SpaTop Rated Massage Center In Ajman Chandrima Spa
Top Rated Massage Center In Ajman Chandrima Spa
 
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...
TEST BANK For Accounting Information Systems, 3rd Edition by Vernon Richardso...
 
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSONNEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
NEEDLE STICK INJURY - JOURNAL CLUB PRESENTATION - DR SHAMIN EABENSON
 
Innovative Minds France's Most Impactful Healthcare Leaders.pdf
Innovative Minds France's Most Impactful Healthcare Leaders.pdfInnovative Minds France's Most Impactful Healthcare Leaders.pdf
Innovative Minds France's Most Impactful Healthcare Leaders.pdf
 
DRAFT Ventilator Rapid Reference version 2.4.pdf
DRAFT Ventilator Rapid Reference  version  2.4.pdfDRAFT Ventilator Rapid Reference  version  2.4.pdf
DRAFT Ventilator Rapid Reference version 2.4.pdf
 
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
Michigan HealthTech Market Map 2024 with Policy Makers, Academic Innovation C...
 
Under Pressure : Kenneth Kruk's Strategy
Under Pressure : Kenneth Kruk's StrategyUnder Pressure : Kenneth Kruk's Strategy
Under Pressure : Kenneth Kruk's Strategy
 
NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022NKTI Annual Report - Annual Report FY 2022
NKTI Annual Report - Annual Report FY 2022
 
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdfChampions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
Champions of Health Spotlight On Leaders Shaping Germany's Healthcare.pdf
 
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac CareStem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
Stem Cell Solutions: Dr. David Greene's Path to Non-Surgical Cardiac Care
 
KEY Points of Leicester travel clinic In London doc.docx
KEY Points of Leicester travel clinic In London doc.docxKEY Points of Leicester travel clinic In London doc.docx
KEY Points of Leicester travel clinic In London doc.docx
 
Gemma Wean- Nutritional solution for Artemia
Gemma Wean- Nutritional solution for ArtemiaGemma Wean- Nutritional solution for Artemia
Gemma Wean- Nutritional solution for Artemia
 
Anxiety, Trauma and Stressor Related Disorder.pptx
Anxiety, Trauma and Stressor Related Disorder.pptxAnxiety, Trauma and Stressor Related Disorder.pptx
Anxiety, Trauma and Stressor Related Disorder.pptx
 
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to CareLGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
LGBTQ+ Adults: Unique Opportunities and Inclusive Approaches to Care
 
Bringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured ApproachBringing AI into a Mid-Sized Company: A structured Approach
Bringing AI into a Mid-Sized Company: A structured Approach
 
Unlocking the Secrets to Safe Patient Handling.pdf
Unlocking the Secrets to Safe Patient Handling.pdfUnlocking the Secrets to Safe Patient Handling.pdf
Unlocking the Secrets to Safe Patient Handling.pdf
 
Letter to MREC - application to conduct study
Letter to MREC - application to conduct studyLetter to MREC - application to conduct study
Letter to MREC - application to conduct study
 
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
TEST BANK FOR Health Assessment in Nursing 7th Edition by Weber Chapters 1 - ...
 
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COMHUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
HUMAN BRAIN.pptx.PRIYA BHOJWANI@GAMIL.COM
 

Cost benifit analysis

  • 1. Cost-benefit Analysis 1 Abdur Razzaque Sarker MHE (Health Economics), MSS (Economics) Health Economics and Financing Research, icddrb and PhD Fellow in Strathclyde University, UK Email: razzaque.sarker@gmail.com
  • 2. What is Cost-Benefit Analysis Cost Benefit Analysis (CBA) is an economic evaluation technique that both costs and consequences (benefits) are measured in monetary unit. Net benefit = Benefits - Costs 2
  • 3.  An intervention should be undertaken if the benefits exceed the costs. Choose the intervention with the highest net benefit if only one intervention can be funded 3
  • 4. Why using CBA  Resources are limited  The intervention program should be economically viable  CBA adopts a broad societal perspective as it includes all costs and all benefits 4
  • 6. Measuring cost of intervention The cost of intervention will be calculated in the same way as other economic evaluation methods (Please see ‘cost analysis’). 6
  • 7. Measuring benefits The ways to measure monetary value of benefits from intervention 1. Cost of illness averted 2. Contingent valuation method (willingness to pay) 7
  • 8. 1. Cost-of-illness averted The cost of illness (COI) is defined as the value of the resources that are expended or foregone as a result of a health problem (like, diseases). 8
  • 9. Perspectives of COI Patient’s or household’s perspective Provider’s perspective Societal perspective 9
  • 10. Costs can be classified into three types  Direct Costs: Direct costs related to treating the patients (example, doctor’s visit, drugs, transport)  Indirect Cost: Loss of productivity of patients and care-givers  Intangible cost: Pain, anxiety, discomfort 10
  • 11. Information needs to be collected Direct cost  How much patients spend for medicine.  How much money was spent for transportation for each visit.  Did you spend any night away from home regarding treatment and spend money to buy food and lodging?  Did you spend any money for any diagnostic tests?  Did you pay consultation fee to the provider? 11
  • 12. Indirect cost Examples:  At the time you got sick with cholera, were you employed?  How much time you waited before receiving this service?  What was your daily wage?  How many days had you been absent from work due to illness?  Did anybody take care of you during your illness?  How many days she/he had been absent from work for giving you care?  What was her/his daily wage?  more…… 12 Information needs to be collected
  • 13. Intangible cost Difficult to measure and often a limitation of the study 13 Information needs to be collected
  • 14. Provider’s actual cost of illness Provider actual cost of illness will be calculated as the provider’s cost for treatment excluding any fees received from the patients for hospitalization, drug, diagnostic tests etc. If government implements vaccination against cholera. The cholera hospitals (wards) can be benefited by reducing their cost for treating cholera patients. 14
  • 15. It includes cost of providers, cost of patients or households and costs of insurance company (if applicable) 15 Cost of illness of society
  • 16. The cost of illness that can be averted, i.e. benefits of the intervention will then be adjusted for time differentials using discount rate. 16
  • 17. 17 Costs Parameters Average cost Standard deviation %of total cost Direct Medical Diagnostic 9.6 (0.1) 75.7 (1) 9 Medicine 148.7 (2) 246 (3.) Registration fee 26.1 (0.3) 130.6 (1.7) Paramedics home visit fee 2.8 (−) 21.5 (0.3) Bed/ Cabin charge 16.9 (0.2) 130.7 (1.7) Direct Non- Medical Transportation cost 140 (1.9) 122 (1.6) 15.6 food items 63(0.8) 85 (1.1) Informal payment 0.7 (−) 9 (0.1) Caregivers payment 0.1 (−) 1 (−) Materials (mug/glass/coil etc) 10.6(0.1) 17 (0.2) Lodging 28 (0.4) 101 (1.3) Caregivers expenditure 113.2 (1.5) 172 (2.3) Total direct cost 559.5 (7.4) 641.7 (8.5) 24.6 In-direct Patients income loss 811 (11) 4,301 (57) Caregivers income loss 908 (12.2) 3,701 (49) Total indirect cost 1,719 (23) 5,656 (75.4) 75.4 Total cost of illness of household 2,278.5 (30.4) 5,668 (75.6) 100 Average household cost for cholera treatment
  • 18. 18 Suppose in Mirpur area, every year 1200 patients are affected by Cholera diseases and it is estimated by our hospital record. A Cost of illness study conducted and estimate the average cost for treating cholera is $40 from societal perspective. We want to minimized the burden of cholera diseases and he initiated the following three intervention A Only Vaccination B Vaccination & hand washing technique C Vaccine, hand washing & Water treatment procedure
  • 19. 19 Intervention Total cost (C) Outcome (No of case averted) A (Vaccine) 10000 200 B ( Vaccine & hand washing) 15000 650 C (Vaccine, hand washing and water treatment) 18000 900 We want to know which intervention is sustainable based on cost benefit analysis?
  • 20. 20 Decision tools:  Net Social Benefit (NSB) = B-C  If B > C we take the intervention, i.e. B-C >0, we accepted that program  If B< C i.e. B-C <0, we must rejected that intervention  If B = C , i.e. B-C =0, we are indifferent i.e. it may be accepted or rejected
  • 21. 21 Intervention Total cost (C) Outcome (No of case averted) A (Vaccine) 10000 200 B ( Vaccine & hand washing) 15000 650 C (Vaccine, hand washing and water treatment) 18000 900 Intervention Total cost (C) Outcome (No of case averted) Total Benefit (B) A (Vaccine) 10000 200 8,000 B ( Vaccine & hand washing) 15000 650 26,000 C (Vaccine, hand washing & Water treatment) 18000 900 36,000 Since average COI is $40 for societal perspective
  • 22. 22 Intervention Total cost (C) Outcome (No of case averted) Total Benefit (B) Net Social Benefit (NSB = B-C ) A (Vaccine) 10000 500 8,000 -2,000 B ( Vaccine & handwashing) 15000 650 26,000 11000 C (Vaccine, hand washing & Water treatment) 18000 900 36,000 18000  If we consider intervention A , here, B – C < 0, Rejected A  In intervention B, here, B –C > 0, ie. NSB >0. Accepted B In intervention C, here, B – C > 0, i,e. NSB >0. Accepted c If we compare all that program, only one intervention can be funded than alternative C is better, causes it gives higher net social benefit.
  • 23. 23 Assigning Money Values in health outcomes  Human Capital Approaches Cost of illness  Contingent valuation method (CVM) Willingness-to- Pay (WTP) Method Willingness –to- Accept (WTP) Method
  • 24.  CVM is a direct method which involves asking a sample of the relevant population question about their willingness to pay (WTP) for a certain product (health intervention program)  Willingness to pay (WTP) is the maximum amount a person would be willing to pay, sacrifice or exchange in order to receive a good or to avoid risk  If individuals answer truthfully, their answers will 24 2. Contingent valuation method (CVM)
  • 25. CV question can be divided into open- ended and discrete choice. Open-ended Using bidding game technique respondents are asked to state their maximum WTP for the benefit of a specific intervention. 25
  • 26. 26 To introduce the cholera vaccine we asked to all household head to know what they willing to pay (max. WTP) to avoidable this loss (COI).  Did you agree to pay for two doses cholera vaccine Yes…..(1) No….(2)  How much you want to pay for two doses oral Cholera vaccine ? BDT……………………
  • 27. 27  In bidding game (like an auction), respondents are offered with a bid for acceptance or rejection. Depending on respondent’s answer, the bid is then lowered or increased until respondent’s maximum WTP is reached.  We bid a price to household head and know about his WTP which may be increasing or decreasing. And finally we select final WTP.
  • 28. Discrete Respondents are offered a bid and asked for either accepting or rejecting. Using different bids in different sub-samples, it is possible to calculate the percentage of respondents who are willing to pay as a function of price (bid). 28
  • 29. 29  Did you agree to pay for two doses cholera vaccine Yes…..(1) No….(2)  If Yes, then which price … 3*2 = 6 USD per family member….....(1) 4*2 = 8 USD per family member…….(2) 4.5*2= 9 USD per family member…….(3) 5*2 =10 USD per family member…….(4) 5.5*2 =11 USD per family member…….(5)
  • 30. Survey for contingent valuation Creating a survey instrument for capturing individuals' WTP (a) designing the hypothetical scenario; (b) creating a scenario about the means of payment Use the survey instrument with a sample of the population of interest 30
  • 31. 31 Where, i= indexes respondents Y= Income E= Education A = Age D=disease or health risk exposure experience WTPi = f ( Yi, Ei, Ai, Di, ... ) Total WTP is achieved by deriving the population average WTP from the data and multiplying it by the population size, N.
  • 32. 32 Note to interviewer: Describe the cholera vaccine, dose and effectiveness both for adult and child to the respondents following the structured description of the product. Would you be willing to pay X Taka for full vaccination for you? Yes No If yes, please explain your reasons for agreeing to pay? 1. The amount is affordable 2. I don’t want to suffer from cholera Other, specify ___________ If no, pls explain your reasons for not wanting to pay? 1. Too expensive 2. Unable to pay Other, specify ____________ Would you be willing to pay XX Taka for full vaccination for other members of your family? Yes No If yes, please explain your reasons for agreeing to pay? 1. The amount is affordable 2. I don’t want to suffer from cholera Other, specify ___________ If no, pls explain your reasons for not wanting to pay? 1. Too expensive 2. Unable to pay Other, specify ____________ What would be the maximum amount you would be willing to pay for yourself? ______________________ Tk What would be the maximum amount you would be willing to pay for other family members? ______________________ Tk
  • 33. Total benefit of the proposed intervention can be calculated by multiplying average WTP with total number of population in interest group. Benefits of the intervention (WTP) will then be adjusted for time differentials using discount rate. Example, Total WTP = 10,000 Taka (after discounting) Total cost of intervention = 8,000 Taka (after discounting) Net benefit = 10,000 – 8,000 Taka = 2,000 Taka Conclusion: If net benefit is higher than zero, then intervention program is acceptable 33